The endogenous cannabinoid system plays an important role in the regulation of gastrointestinal (GI) function in health and disease. Endocannabinoid levels are regulated by catabolic enzymes. Here, we describe the presence and localization of monoacylglycerol lipase (MGL), the major enzyme responsible for the degradation of 2-arachidonoylglycerol. We used molecular, biochemical, immunohistochemical and functional assays to characterize the distribution and activity of MGL. MGL mRNA was present in rat ileum throughout the wall of the gut. MGL protein was distributed in the muscle and mucosal layers of the ileum, and in the duodenum, proximal and distal colon. We observed MGL expression in nerve cell bodies and nerve fibers of the enteric nervous system. There was extensive colocalization of MGL with PGP 9.5 and calretinin immunoreactive neurons, but not with nitric oxide synthase. MGL was also present in the epithelium and highly expressed in the small intestine. Enzyme activity levels were highest in the duodenum and decreased along the gut with lowest levels in the distal colon. We observed both soluble and membrane-associated enzyme activities. The MGL inhibitor URB602 significantly inhibited whole gut transit in mice; an action that was abolished in cannabinoid 1 receptor-deficient mice. In conclusion, MGL is localized in the enteric nervous system where endocannabinoids regulate intestinal motility. MGL is highly expressed in the epithelium, where this enzyme may have digestive or other functions yet to be determined. Duncan et al. 3 
CANNABINOID (CB) RECEPTORS (termed CB 1 and CB 2 ), the endogenous ligands for these receptors (endocannabinoids) and their biosynthetic and catabolic enzymes form the endocannabinoid system (11; 12) . This novel regulatory system has important roles in physiology, and has been linked to a number of pathophysiological conditions, notably disorders of energy metabolism (31) . There is increasing evidence for significant roles of the endocannabinoid system in the control of gastrointestinal and liver (patho)physiology (15; 22; 37; 44; 45; 47) . CB 1 receptors are predominantly expressed in the enteric nervous system (ENS), where they are primarily localized to prejunctional nerve terminals and regulate transmitter release (15) . We recently described the localization of CB 2 receptors in the ENS (16) . These receptors appear to be active under pathophysiological conditions and serve to limit the extent of enhanced motility seen under these circumstances (30) . The natural endogenous ligands for the CB receptors, anandamide and 2-arachidonoylglycerol (2-AG), have affinity at both CB 1 and CB 2 receptors (10; 21; 32). Unlike classical transmitters, endocannabinoids are synthesized and released 'on demand'. Recently, their biosynthetic and inactivation pathways have been identified. Anandamide is an N-acylethanolamine formed from the cleavage of N-arachidonoyl phosphatidylethanolamine catalyzed by a unique phospholipase D (1) . The biosynthesis of 2-AG comprises the sequential action of phospholipase C and diacylglycerol lipase (DGL) on membrane phospholipid (1, 42) . Anandamide and 2-AG are present within the GI tract at levels able to activate CB receptors. Anandamide is present in ileal and colonic tissues at levels of 0.27 nmol/g and 0.036 nmol/g, whereas 2-AG levels are 44.1 nmol/g and 18.7 nmol/g, respectively Duncan et al. 5 (38) . Such regional differences of endocannabinoids along the GI tract may reflect functional differences in their actions in the ileum and colon.
Inactivation pathways for endocannabinoids are thought to involve a putative endocannabinoid membrane transporter (11; 12; 33) . Once taken up into the cell they are degraded by the enzymes fatty acid amide hydrolase (FAAH; also known as anandamide amidohydrolase) and monoacylglycerol lipase (MGL; also known as monoglyceride lipase) (8; 9; 13; 14, 17) . FAAH has been shown to catalyze the hydrolysis of both anandamide and 2-AG (8; 9; 17) . FAAH mRNA and protein expression is present in the GI tract (4) and inhibition significantly attenuates intestinal motility in mice indicating enhanced local endocannabinoid levels are functionally significant (23) . Genetic ablation of FAAH in mice results in a 2.8 fold increase of ileal anandamide content with respect to wildtype controls (4) , and these mice are significantly protected against inflammation in the 2,4-dinitrobenzene sulphonic acid (DNBS) model of experimental colitis (29) .
The second enzyme involved in endocannabinoid inactivation, MGL, is a serine hydrolase that converts 2-AG to fatty acids and glycerol (13) . MGL mRNA and protein have been localized to nerve fibers and soma in areas of the brain that express high levels of CB 1 receptors (13).
URB602 is a rapidly acting, non-competitive inhibitor of MGL (25) , that increases 2-AG levels in hippocampal slice cultures (25; 27) and enhances stress-induced analgesia by raising local 2-AG levels when administered into the periaqueductal grey matter (20) . However, more recent papers have described anti-nociceptive actions of URB602 when administered intraperitoneally Duncan et al. 6 and subcutaneously in the carrageenan and formalin inflammatory pain models, respectively (6; 18) .
Although a physiological role of FAAH has been described in the GI tract (4; 38), the distribution and function of MGL within the GI tract is unknown. The purpose of this study was to examine the distribution and function of MGL in the rodent GI tract in order to provide a better understanding of the endocannabinoid system within the gut. 
MATERIALS AND METHODS

Animals
RT-PCR
Total RNA was isolated using TRIzol™ reagent (Invitrogen, Carlsbad, CA, USA). RNA was reverse transcribed into cDNA using Superscript II reverse transcriptase (Invitrogen) according to 
Western Blotting
For the first experiment, full thickness ileal segments, muscle and submucosal layers (containing the ENS) and mucosa (removed by scraping the opened intestine with a microscope slide, n=6) were collected. For the second experiment, full thickness tissues were collected from duodenum, ileum, proximal and distal colon (n=5). Samples were immediately suspended in enzyme inhibitors (11697498001; Roche Diagnostics, Indianapolis, IN, USA), homogenized and protein concentrations were determined. Proteins were separated with SDS-PAGE (10%), then transferred onto a nitrocellulose membrane, as previously described (34) . Membranes were then incubated in blocking solution composed of 5% fat-free milk and tris-buffered saline 
Immunohistochemistry
Whole mount preparations of longitudinal muscle-myenteric plexus, and submucosal plexus (SMP) were prepared as previously described (41) . Briefly, the mucosa was removed, the submucosal layer was then carefully separated from the layers beneath, and then the circular 
Enzyme Activity
Frozen tissue segments were thawed and homogenized in 10 volumes of TE buffer (50 mM Tris, 1 mM EDTA, pH 7.4) using a Polytron homogenizer. Following centrifugation at 30 000 g for 30 min, the supernatant layer was collected and the pellet was homogenized once more in 10 Duncan et al. 11 volumes of TE buffer. Following centrifugation as before, the supernatant layers were combined and stored at -80°C. The pellet was re-suspended in 3 volumes of 50 mM Tris buffer, pH 7.4 and stored at -80°C. Assays of MGL activity were conducted using minor modifications of methods described by Vandevoorde et al. (46) . In brief, thawed samples were diluted in TE buffer to a suitable protein concentration (~ 1:100 wet weight for particulate preparations and ~1:1000 for soluble fractions) and pre-incubated with inhibitor at 37°C for 10 min, before addition of 2-oleoylglycerol (2OG, 100 µM, Sigma-Aldrich; containing 1-2 kBq 2-oleoyl-[ 3 H]glycerol, American Radiolabelled Chemicals). After incubation at 37°C for 15 min, the reaction was terminated by the addition of 2 volumes of chloroform:methanol (1:1) and mixing.
Chloroform (1 volume) was added to separate the phases, before removing an aliquot of the supernatant layer containing liberated [ 3 H]-glycerol for liquid scintillation counting.
Upper GI transit studies
After an overnight fasting period (water ad libitum), a marker was administered orally to assess upper GI transit, as described in detail by others (39; 40). 30 min after intraperitoneal (i.p.)
administration of URB602 (20 or 40 mg/kg) or vehicle (10% DMSO/Tween 80 in saline (6) 
Statistical analysis
Data are expressed as the mean ± s.e.m and analysed with Student's t tests or using a one way analysis of variance with Bonferroni-corrected t tests. P < 0.05 was considered significant.
RESULTS
MGL mRNA is present in the rat ileum
MGL mRNA was present in samples of full-wall thickness ileum, as well as in the muscle and submucosal layers that contain the ENS and the mucosa ( Figure 1A) . No band was detected in the absence of the template. RNA from the samples were reverse transcribed or mock-treated prior to PCR. We observed no bands in the RNA sample that was mock-treated, indicating amplification was not due to genomic DNA contamination of the RNA sample (data not shown).
MGL protein is expressed throughout the rat GI tract
Western blot analyses confirmed the presence of MGL protein in homogenates of rat ileal tissue ( Figure 1B ). MGL was detected in full-wall thickness samples of ileum, and was also present in the muscle and submucosal layers and the mucosa. The bands were ~33 kDa, which is an appropriate molecular weight, based on previously published work (14; 24) . Preabsorption of this antibody with the immunizing peptide has previously been shown to abolish detection of bands (14) . Semi-quantitative densitometric measurement, expressed as a ratio of actin content in each sample, indicated that the muscle and submucosal layer containing the enteric plexuses had higher levels of MGL expression when compared to the mucosa ( Figure 1C ). MGL is expressed along the length of the GI tract in the full-wall thickness samples of duodenum, ileum, proximal colon and distal colon ( Figure 1B) . The lowest levels were found in the duodenum, whereas no significant differences were found between the levels in ileum, proximal and distal colon ( Figure 1D ). In the proximal colon, we observed a fairly prominent double band, which has also been reported in brain homogenates and may be explained by the Duncan et al. 15 presence of different MGL isoforms due to different leader sequences reported in MGL cDNA (14; 24) .
MGL is expressed by enteric neurons and in the epithelium of the GI tract
Cross sections of the duodenum, ileum, proximal and distal colon showed MGL immunoreactivity to be most intense within the MP with relatively lower levels in the SMP ( Figure 2 ). MGL staining was also observed at the base of the crypts and within the epithelium, notably in the small intestine ( Figure 2 , left column). In whole mount preparations, MGL immunoreactivity was present in neurons and nerve fibers within both the myenteric and submucosal plexuses along the rat GI tract (Figures 3 & 4) . We observed that the duodenum and ileum had more fibrous staining than the other regions of the gut ( Figures 3A-B and 4A-B ). PGP 9.5, a marker of neuronal populations within the ENS, was used for double staining with MGL. Cell counts were used to quantify the number of cells per ganglia that expressed MGL as a percentage of PGP 9.5 positive neurons. Most of the PGP 9.5 labeled neurons also expressed MGL: duodenum (90.2% ± 1.5%), ileum (86.5% ± 1.7%), proximal (82.0 % ± 2.2%) and distal colon (86.7% ± 2.0%). There were no significant regional differences noted. Mean values within the SMP were: duodenum (89.9% ± 1.7%), ileum (86.5% ± 1.9%), proximal (82.6% ± 2.1%) and distal colon (91.7% ± 1.5%). Within the SMP, the proximal colon had significantly lower MGL expressing cells than the duodenum (P<0.05), and the distal colon (P<0.01). The use of calretinin, a Ca 2+ binding protein localized on both excitatory motor neurons projecting to longitudinal muscle as well as ascending interneurons, was also used for double labeling with Duncan et al. 16 MGL ( Figure 5 ). Cell counts show that MGL is expressed in the majority (>80%) of calretinin positive cells within the MP and SMP of all the regions of the GI tract (data not shown).
Inhibitory motor neurons are known to express neuronal NOS (nNOS). Using an antibody raised against nNOS, we determined that very little colocalization of MGL and NOS was observed within the MP of rat GI tract ( Figure 5 ).
MGL is functionally active in the rat ileum
The soluble fraction of extracts from rat GI tissues was assessed for the ability to hydrolyze 2oleoylglycerol (2-OG) in vitro, according to minor modifications to the method of Vandevoorde et al. (46) . Using this assay, a gradation of activity was observed in the gut ( Figure 6A ), such that activity in the small intestine was 4-8 times higher than in the colon. Separating the mucosa in the ileum from the muscle and submucosal layers allowed determination of a much higher MGL activity in this region than in the muscle and submucosal layers, where activity was relatively low ( Figure 6B ). MGL activity in all of the soluble fractions of GI tissue was completely inhibited in the presence of 1 µM methyl arachidonyl fluorophosphonate (MAFP, data not shown).
Additional MGL activities have been identified in mouse tissues which are associated with membrane fractions (2; 35). We, therefore, addressed whether the membrane fraction from rat GI tissue was able to hydrolyze 2-OG and whether FAAH (also present in the membrane fraction) contributes to this activity, by evaluating MGL activity in the absence and presence of the FAAH inhibitor URB597 (1 µM). In the ileal muscle and mucosal layers, membrane MGL activity was observed ( Figure 6C ) and this was found to be insensitive to URB597 (140 ± 15 Duncan et al. 17 nmol/min/mg protein compared to 134 ± 57 in the presence of URB597). In contrast, the hydrolysis of 2-OG by membrane preparations from the ileal mucosa was reduced in the presence of URB597, indicating that FAAH contributed to this activity (521 ± 71 nmol/min/mg protein basal activity compared to 318 ± 27 in the presence of URB597). No regional differences of URB597-sensitivity was observed in the membrane fractions of samples of duodenum, ileum or colon ( Figure 6D ). The ability of URB602 (10 -7 to 10 -4 M) to inhibit MGL was assessing using preparations from the rat ileal mucosa because this tissue had the highest levels of MGL activity ( Figure 6E ). URB602 was able to inhibit 2-OG hydrolysis in both fractions, though the soluble fractions appear to be more sensitive to the inhibitory actions of URB602. MAFP 
The MGL inhibitor URB602 inhibits whole gut transit in mice
URB602 at doses of 20 and 40 mg/kg tended to reduce upper GI transit ( Figure 7A ) and slow colonic propulsion ( Figure 7B ), though these did not reach statistical significance. When taken together as whole gut transit, it was apparent that URB602 dose-dependently inhibited transit Duncan et al. 18 (P<0.05, Figure 7C ) compared to the vehicle control group. In CB 1 receptor-deficient mice, transit times were accelerated compared to wild type mice in agreement with previous reports (48) . The inhibitory action of 40 mg/kg URB602 on whole gut transit was absent in these mice ( Figure 7D ), indicating CB 1 receptor involvement in the inhibitory action. Preliminary data indicate that 40mg/kg URB602 also attenuates upper GI transit in rats (62.6 ± 4.0% of intestine travelled compared to 75.8 ± 2.5% in vehicle-treated controls, P<0.05).
DISCUSSION
We report that the endocannabinoid hydrolyzing enzyme monoacylglycerol lipase (MGL) is widely distributed in the rodent GI tract. Furthermore, MGL is functionally active along the GI tract and can be inhibited by the non-competitive MGL inhibitor URB602 (25) , resulting in slowing of transit along the gut.
We show that MGL mRNA and protein are expressed within the muscle and mucosal layers of the rat ileum as well as in the duodenum, ileum, proximal and distal colon. Semi-quantification of MGL protein expression demonstrates a significantly higher amount of MGL protein in the layers of the gut that contain the enteric plexuses compared to mucosal layer. These data fit well with the extensive expression of MGL immunoreactivity in neurons of the ENS. When examined with these approaches, there is an increasing trend of MGL protein expression from duodenum to distal colon, which potentially may account for lower levels of 2-AG reported within the colon (38) .
In order to determine the overall regional activity levels within the GI tract, we employed an assay of 2-OG hydrolysis. MGL is a soluble, cytoplasmic enzyme associated with the cell membrane (2) . Therefore, we assessed the soluble fraction from rat gastrointestinal tissues for in vitro hydrolysis of 2-OG. High levels of MGL activity were found in the ileal mucosa with relatively low levels observed within the muscle and submucosal layers, despite the apparently high levels of protein expression. In full-wall thickness samples, MGL activity is highest in the duodenum and ileum, with lower activity observed in the colon. These data are in direct contrast to our MGL expression data, where the duodenum expressed the lowest level of protein expression. It could be the case that MGL represents only a percentage of 2-OG hydrolyzing enzymes within gastrointestinal tissues. 2-AG hydrolysis has been also reported by "novel MGL" activities present in a microglial cell line, as well as 2 uncharacterized enzymes, ABHD6 and ABHD12, described in the mouse brain (2) . The inverse relationship between the expression levels of MGL detected by our antibody, and activity in the soluble fractions of this enzyme are striking, so it might be that there is a unique regulation of 2-AG in the GI tract by a number of enzymes or that the expression of the antigenic epitope seen by the antibody does not fully reflect functional enzyme activity. Further studies are required to address this issue.
As noted above, a novel MGL has recently been described in the mouse microglial line BV-2.
These cells do not express MGL mRNA but retain the ability to hydrolyze 2-AG. Hydrolysis of 2-AG is less efficacious in BV-2 cells when compared to MGL-expressing neurons and is also less sensitive to the inhibitory actions of both MAFP and URB602 (35) . In neurons, MGL activity is equally distributed between membrane and soluble fractions, whereas "novel MGL" is enriched in the membrane fraction in BV-2 cells. To address whether "novel MGL" is expressed in the GI tract, we evaluated the membrane fractions of our homogenates and found low, but significant levels of 2-OG hydrolyzing activity. The activity profile between mucosa and muscle was similar to that observed in the soluble fraction, but there were no regional differences in the full thickness samples along the GI tract. In the membrane fractions, MAFP was less potent as an inhibitor of MGL activity than in the soluble fraction. To further test the differential sensitivity to MGL inhibitors, we then compared the ability of URB602 to inhibit MGL in the soluble and membrane fractions of ileal mucosa. In these experiments, the soluble fraction is more sensitive to URB602; taken together with the residual activity in the presence of MAFP we consider it likely that there is a "novel MGL" present in the GI tract.
The antibody we use is directed against the "classical" MGL which has been cloned and characterized. Cells expressing "novel" MGL do not have "classical" MGL mRNA, but are nevertheless able to hydrolyze 2-AG. We propose that the enzyme activity we report is "Total 2-AG hydrolysis" from the combined activities of "classical" MGL, "novel" MGL, possibly ABHD6, ABHD12 as well as potentially other, as yet unidentified, enzymes. This would also explain some of the apparent discrepancy between our expression levels, cell counts and hydrolyzing activity, as we are only characterizing the expression profile of a proportion of the total 2-AG hydrolyzing enzymes.
There has been some controversy about the selectivity of URB602 for MGL over FAAH (46) . In our hands URB602 significantly inhibited MGL activity, whereas the same concentration only slightly inhibited FAAH activity. These data are in agreement with studies in BV-2 cell lines (35) and brain slice cultures (27) where a small inhibition of FAAH activity was observed at higher concentrations of URB602. These studies report no accompanying rise in anandamide in the preparations and so indicate this small effect on FAAH is unlikely to be relevant.
The chemical coding of neurons within the ENS has been well established (7; 26) . We report MGL to be expressed on the majority of enteric neurons, including a subpopulation of excitatory motor neurons that innervate longitudinal muscle within the gut responsible for regulation of motility patterns (7; 26) . Curiously, this enzyme was virtually absent from neurons that express NOS, which are inhibitory motor neurons innervating the circular muscle, as well as a population of descending interneurons (7; 26) . It is interesting to note that these neurons do not express the CB 1 The main focus of this paper is the role of MGL as an endocannabinoid hydrolyzing enzyme, but this enzyme does have other functions. The high expression we observe in the epithelia are in agreement with a previous study (19) using the intestinal Caco-2 cell line. This cell line can be used as a model of mature villus cells in the intestinal epithelium, and the authors report that they contain the MGL gene and are able to metabolize sn-2-monoacylglycerol (19) . Intestinal MGL can also be regulated by diet, rats being fed a high fat diet had significantly elevated MGL expression and activity compared to the low fat diet group (5) . These studies indicate MGL plays an important role in lipid regulation and metabolism. Nomura and co-workers (36) recently reported potent inhibition of MGL using organophosphorus (OP) compounds. In their assay, OP inhibition of MGL resulted in increased 2-AG levels and decreased arachidonic acid levels, which in the gut, would have anti-inflammatory properties. Furthermore, the authors demonstrate that OP compounds activate CB 1 receptors by the metabolic stabilization of 2-AG, which would explain why the effects of MGL inhibition we observed were absent in CB 1 receptor-deficient mice. The widespread distribution of MGL throughout the gut we report, not only contributes to knowledge of endocannabinoid signaling within the gut, but suggest MGL may be a suitable target in the treatment of obesity or as an anti-inflammatory agent.
In conclusion, we report that MGL is functionally expressed within the GI tract and novel 2-AG hydrolyzing enzymes are also present in cell membrane fractions in the gut. MGL is present in neurons and epithelia and has different activity profiles along the gut, indicating this enzyme could be involved in the regulation of many physiological processes. Despite the low potency of Duncan et al. 24 URB602, we were able to demonstrate inhibition of MGL in the GI tract in both in vitro and in vivo assays. These data add further to the elucidation of the endocannabinoid system and the GI tract. URB602 might also be used as a lead compound to develop more potent and specific MGL inhibitors to further elucidate the role of MGL in GI function. Intense immunoreactivity was observed in the myenteric and submucosal plexus and epithelia.
Figure Legends
Scale bars: 100 µm. In CB 1 receptor-deficient mice, the inhibitory actions of 40 mg/kg URB602 on whole gut transit were absent (D) indicating CB 1 receptor involvement in this response. It should be noted that the whole gut transit is faster in the vehicle-treated CB 1 receptor-deficient mice than in wild type animals.
